Change of Name (0112H)
20 May 2011 - 9:01PM
UK Regulatory
TIDMONG
RNS Number : 0112H
Oxford Nutrascience Group PLC
20 May 2011
20 May 2011
Oxford Nutrascience Group plc
("Oxford Nutrascience" or "the Company")
Change of name to Oxford Pharmascience Group
Oxford Nutrascience the speciality pharmaceutical company that
uses advanced pharmaceutic technologies to reposition medicines
adding value to generic and soon to be off patent Active
Pharmaceutical Ingredients (API's). announces that, following
recent shareholder approval, the Company's name has changed to
Oxford Pharmascience Group Plc. The Company will commence trading
on the AIM Market of London Stock Exchange Plc under this new name
and under the trading symbol "OXP" from Monday 23 May 2011.
The new name reflects the Company's strategy which has evolved
significantly during the last 12 months as it has expanded its
technology base and expertise away from nutraceuticals to
development and licensing of advanced medicines. The Company's
technology portfolio includes superior chewable tablets, liquid
suspensions and solid state suspensions (soft chews) as well as
drug delivery technologies to achieve targeted release or taste
masking effects. The Company is using these technologies to develop
a range of medicines initially with focus on NSAIDs, statins and
calcium focusing primarily on the pharmaceutical sector.
The Company's new website address will be
www.oxfordpharmascience.com where further information on the
Company can be found including information as required by AIM Rule
26.
- Ends -
For further information:
Oxford Pharmascience Group Plc
Nigel Theobald, Chief Executive +44 1865 854874
Mark Way, Investor and Media Relations +44 7786 116991
ZAI Corporate Finance (Nominated Adviser)
John Depasquale +44 20 7060 2220
Sarang Shah +44 20 7060 2220
About Oxford Pharmascience Group Plc
-- Oxford PharmaScience are specialists in the repositioning of
medicines via reformulation using advanced pharmaceutic
technologies to add value to generic and soon to be generic
drugs;
-- Technology portfolio includes superior chewable tablets,
liquid suspensions, and solid state suspensions (soft chews) as
well as modified drug delivery technologies to achieve either taste
masking or targeted release effects.
-- The company uses its technologies to develop Drug Master
Files (DMF's) and full CTD dossiers (drug registration dossiers)
for a range of medicines initially with focus on NSAIDs, statins
and calcium.
-- Oxford Pharmascience works closely with leading academic
institutions to further advance its intellectual property portfolio
to apply to generic and soon to be generic drugs.
This information is provided by RNS
The company news service from the London Stock Exchange
END
CANSEUFSSFFSEII
Oxford Nutrascience (LSE:ONG)
Historical Stock Chart
From May 2024 to Jun 2024
Oxford Nutrascience (LSE:ONG)
Historical Stock Chart
From Jun 2023 to Jun 2024
